Reset filters
Publication Types
27 May 2021
  • Update from the Fleischner Society Task Force for imaging in pulmonary hypertension, Martine Rémy-Jardin
  • Molecular imaging of pulmonary vascular disease using microvascular endothelial cell ligands, Jocelyn Dupuis
  • MRI to assess pulmonary vascular changes and PH progression, Jens Vogel-Claussen
  • Xenon magnetic resonance imaging signatures of PH, Sudarshan Rajagopal 
  • Synchrotron-based phase contrast micro-CT imaging of pulmonary vascular disease in human tissue and animal models, Karin Tran-Lundmark 
PVRI Digital Webinar Series
4 May 2021
  • Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin, Iona Cuthbertson
  • Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension, Prakash Chelladurai
  • Implication of the histone methyltransferase “g9a” in pulmonary arterial hypertension, Charifa Awada 
  • Perinatal exposure to serotonin re-uptake inhibitor causes mild pulmonary hypertension in adult female rats, Barbora Kaftanová 
  • Endothelial overexpression of sirt3 protects the metabolic etiology in PAH, Anandharajan Rathinasabapath
  • Axl is a novel modulator of bone morphogenetic protein receptor 2 in pulmonary arterial hypertension, Tatyana Novoyatleva 
  • Equivalent outcomes for hereditary and idiopathic pulmonary arterial hypertension in children; an analysis from a national Australian registry, Katherine Kearney Graham 
  • Effect of macitentan across prognostic age groups in patients with pulmonary arterial hypertension (PAH), Richard Channick
  • Validation of artificial intelligence artery-vein Classification for Contrast CT imaging in PH subjects, Pietro Nardelli
  • Efficacy in patient subgroups in the INCREASE Trial, a phase III Trial to evaluate inhaled Treprostinil in patients with pulmonary hypertension due to parenchymal Lung Disease, Victor Tapson
  • Acetazolamide and high altitude pulmonary edema prevention, Erik Swenson 
  • Telomeric Tankyrases: a novel and propitious target to ameliorate the maladaptation phenomena at heights, Manjula Miglani 
PVRI Digital Webinar Series
25 March 2021
  • SARS-1, MERS, SARS-2 and more: are coronavirus infections an ubiquitous part of our lives? Albert Osterhaus
  • Endothelitis and aberrant angiogenesis – mechanisms of COVID-19 induced vascular injury, Danny Jonigk
  • Venous thromboembolism in COVID-19: Prevalence and clinical picture, Stavros Konstantinides
  • ACE-II receptors – Modulation of PVD in COVID-19? Anna Hemnes
  • Tricuspid regurgitation, as proxy for acute pulmonary hypertension, and its association with short-term outcome in severe Covid-19, Claes Frostell 
  • Venous and arterial thromboembolism in COVID-19: a systematic review with meta-analysis, Vicky Mai
PVRI Digital Webinar Series
25 February 2021
  • Health and wearables: Is this the dawn of a new age for cardiovascular medicine? Martin Cowie
  • Professor Sheila Glennis Haworth Memorial Lecture - Translational Research on PAH, Jason Yuan 
  • Biomarker Analysis of the PULSAR Study: An Ongoing Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of PAH, Marc Humbert
  • Switching from PDE5i to riociguat in patients with PAH: The REPLACE study, Raymond Benza
  • A diagnostic miRNA signature for PAH using a consensus machine learning approach (Rupert Swift Award 2021), Niamh Errington
PVRI Digital Webinar Series
11 February 2021
  • The view of the World Heart Federation (WHF), Fausto Pinto
  • Update on the Global Burden of PH Project of the Institute for Health Metrics and Evaluation (IHME), Sophia Emmons-Bell
  • PVRI GoDeep: Perspectives of a global meta-registry, Werner Seeger
  • Mortality of idiopathic/hereditary and connective tissue disease-associated pulmonary arterial hypertension: the data from first single center prospective registry in Indonesia, Anggoro Budi Hartopo
  • Triple therapy in pulmonary arterial hypertension in an expert centre in Mexico City. Real-life results, Humberto Garcia-Aguilar
PVRI Digital Webinar Series